证券时报作为唯一总部在深圳的央级媒体，始终与中国资本市场同呼吸、共命运，是中国资 本市场乃至整个中国经济的重要见证者与参与者。作为中国财经媒体"国家队"，证券时报希 望通过搭建高质量的交流平台，聚焦行业前沿动态，链接产业资本资源，促进科研成果转 化，共同探讨生物医药行业高质量发展的未来路径，持续赋能生物医药行业的创新发展。 随着人工智能与生物医药的深度融合，粤港澳大湾区正成为全球"AI+创新药"发展的前沿阵地。 为抢抓行业机遇、搭建高端对话平台， 卫光控股联合证券时报社，将于 3月10日 在深圳市光明区 举办 智汇湾区·药创未来--粤港澳大湾区"AI+创新药"发展与赴港机遇沙龙 。 本次活动得到了深圳市金融办和深圳市金融稳定发展研究院的大力支持，将汇聚国内知名企业、 科研专家及资本方，聚焦AI技术赋能、产业转化及国际化路径，助力大湾区生物医药产业抢占全 球创新高地。 近年来，随着港股上市规则优化以及大湾区资本联动加强，生物医药企业赴港上市迎来政策窗口 期。 本次活动特别邀请了港交所相关负责人深度解读企业赴港上市的核心痛点、合规要求及国际 化路径。通过案例剖析与一对一交流环节，帮助企业精准匹配资本需求，高效链接 ...

Group 1 - The core viewpoint of the articles highlights a surge in local biopharmaceutical companies applying for listings on the Hong Kong Stock Exchange, driven by favorable market conditions and the need for funding to support research and development [1][5][8] - A significant portion of the companies applying for listings are early-stage, unprofitable biotech firms, with many utilizing the special listing channel for unprofitable companies established under Chapter 18A of the Hong Kong Stock Exchange [2][3] - The current wave of IPOs is characterized by a mix of newly established biotech firms and more mature companies with established business models, indicating a diverse range of funding needs and market strategies [3][4] Group 2 - The capital market's cyclical recovery has provided a crucial external window for these listings, with the Hang Seng Innovation Drug Index showing a rebound of over 200% in the past two years, reflecting a renewed focus on quality assets [5][6] - The internal dynamics of the biopharmaceutical industry, combined with the improved liquidity and sentiment in the Hong Kong market, have created a conducive environment for these companies to seek public funding [7][8] - However, there is a growing concern about market congestion, with over a hundred biopharmaceutical companies in the IPO preparation queue, leading to potential differentiation challenges among these firms [8][9] Group 3 - The market is expected to experience significant polarization, with a clear divide between high-value companies and those with weaker clinical data or less innovative pipelines, which may struggle to attract investment [9][10] - Companies that can withstand market fluctuations are those with unique pipelines and a focus on addressing real clinical needs, as opposed to those merely following trends [10][11] - The long-term success in the biopharmaceutical sector will depend on the ability to build competitive advantages through innovative solutions that meet clinical demands, rather than relying on speculative concepts [11]

Core Viewpoint - The ongoing trend of biopharmaceutical companies listing in Hong Kong is driven by the need for capital and the advantages of Hong Kong's research infrastructure and regulatory environment, which support mainland companies in entering international markets [2][8]. Group 1: IPO Activity - Over 12 biopharmaceutical companies, including Anhui Huaheng Bio, Betta Pharmaceuticals, and Xuan Bamboo Bio, have submitted IPO applications in Hong Kong since mid-September [1]. - Xuan Bamboo Bio's stock opened at HKD 29.46, a 153.97% increase from its issue price of HKD 11.6, with a market capitalization exceeding HKD 15 billion [1]. Group 2: Financial Performance - Xuan Bamboo Bio reported revenues of HKD 2.9 million, HKD 30.09 million, and HKD 17.89 million for 2023, 2024, and the first half of 2025, respectively, while experiencing losses of HKD 300 million, HKD 556 million, and HKD 111 million during the same periods [6]. - The company has a cash balance of HKD 8.558 million as of mid-2025, indicating a need for ongoing funding to support its operations and R&D [6]. Group 3: Product Pipeline and Market Competition - Xuan Bamboo Bio has three core products approved for market, including KBP-3571, a proton pump inhibitor (PPI) for treating digestive diseases, which has become a significant revenue source [3][4]. - The PPI market in China is competitive, with major players like Rabeprazole and Esomeprazole dominating, and Xuan Bamboo Bio faces challenges from generic competitors as patents expire [5][6]. - The company is expanding the indications for KBP-3571 to include reflux esophagitis, with clinical trials currently in Phase III [5]. Group 4: Industry Insights - The capital market is increasingly recognizing the value of innovative biopharmaceutical companies, emphasizing the importance of balancing cash flow with R&D pipeline development [2][8]. - Listing in Hong Kong allows companies to attract global capital and accelerate drug development and market promotion, but they must demonstrate tangible results to maintain investor interest [8].

Core Viewpoint - The ongoing trend of biopharmaceutical companies going public in Hong Kong is driven by the need for funding and the advantages of Hong Kong's research infrastructure and regulatory environment [2][3] Group 1: IPO Activity - Over 12 biopharmaceutical companies have submitted IPO applications in Hong Kong since mid-September, covering areas such as innovative drug development and vaccines [2] - Xuan Zhu Biotech, which completed its IPO application in June, opened at HKD 29.46 per share, a 153.97% increase from its issue price of HKD 11.6, with a market capitalization exceeding HKD 15 billion [2] - The company plans to use 45% of the raised funds for core product R&D, 14% for key product development, and 20% for enhancing commercialization and marketing capabilities [2] Group 2: Market Dynamics - The collaboration between mainland Chinese pharmaceutical companies and Hong Kong is expected to deepen in product R&D, market strategy, and capital operations [3] - The capital market is returning to the essence of value recognition for biopharmaceutical assets, with innovative companies gaining continuous attention [3] Group 3: Competitive Landscape - Xuan Zhu Biotech has three core products approved for market, including KBP-3571, which has become a major revenue source [4] - The PPI market in China has remained above CNY 10 billion from 2018 to 2024, but competition is intensifying due to the inclusion of several common PPIs in centralized procurement [5] - Xuan Zhu Biotech is expanding the indications for KBP-3571 to include reflux esophagitis, which is currently in Phase III clinical trials [6] Group 4: Financial Performance - Xuan Zhu Biotech is experiencing revenue growth but also increasing losses, with revenues of CNY 2.9 million and CNY 30.09 million in 2023 and 2024, respectively, and total losses of CNY 3 billion and CNY 5.56 billion [7] - The company has over ten drug assets in development, with a significant focus on R&D spending, which was CNY 3.84 billion, CNY 2.85 billion, and CNY 1.06 billion for 2023, 2024, and the first half of 2025, respectively [8] Group 5: Future Outlook - The biopharmaceutical industry is characterized by high investment, long cycles, and high risks, leading to a continuous need for funding [7] - Companies must demonstrate tangible results in clinical value or commercial revenue to attract capital and resources in a competitive market [9]